Abstract
Albeit the removal of Asn297 glycans of IgG perturbs the overall conformation and flexibility of the IgG CH2 domain, resulting in the loss of Fc-ligand interactions and therapeutically critical immune effector functions, aglycosylated full-length IgG antibodies are nearly identical to the glycosylated counterparts in terms of antigen binding, stability at physiological or low temperature conditions, pharmacokinetics, and biodistribution. To bypass the drawbacks of glycosylated antibodies that include glycan heterogeneity and requirement of high capital investment for biomanufacturing, aglycosylated antibodies have been developed and several are under clinical trials. Comprehensive cellular and bioprocess engineering has enabled to produce highly complex aglycosylated IgGs in a simple bacterial cultivation with comparable production level as that of mammalian cells. Moreover, extensive engineering of aglycosylated Fc has converted the aglycosylated IgG antibodies into a new class of effector functional human immunotherapeutics.
| Original language | English |
|---|---|
| Pages (from-to) | 128-139 |
| Number of pages | 12 |
| Journal | Current Opinion in Biotechnology |
| Volume | 30 |
| DOIs | |
| Publication status | Published - 2014 Jan 1 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Biotechnology
- Bioengineering
- Biomedical Engineering
Cite this
Aglycosylated full-length IgG antibodies : Steps toward next-generation immunotherapeutics. / Ju, Man Seok; Jung, Sang Taek.
In: Current Opinion in Biotechnology, Vol. 30, 01.01.2014, p. 128-139.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Aglycosylated full-length IgG antibodies
T2 - Steps toward next-generation immunotherapeutics
AU - Ju, Man Seok
AU - Jung, Sang Taek
PY - 2014/1/1
Y1 - 2014/1/1
N2 - Albeit the removal of Asn297 glycans of IgG perturbs the overall conformation and flexibility of the IgG CH2 domain, resulting in the loss of Fc-ligand interactions and therapeutically critical immune effector functions, aglycosylated full-length IgG antibodies are nearly identical to the glycosylated counterparts in terms of antigen binding, stability at physiological or low temperature conditions, pharmacokinetics, and biodistribution. To bypass the drawbacks of glycosylated antibodies that include glycan heterogeneity and requirement of high capital investment for biomanufacturing, aglycosylated antibodies have been developed and several are under clinical trials. Comprehensive cellular and bioprocess engineering has enabled to produce highly complex aglycosylated IgGs in a simple bacterial cultivation with comparable production level as that of mammalian cells. Moreover, extensive engineering of aglycosylated Fc has converted the aglycosylated IgG antibodies into a new class of effector functional human immunotherapeutics.
AB - Albeit the removal of Asn297 glycans of IgG perturbs the overall conformation and flexibility of the IgG CH2 domain, resulting in the loss of Fc-ligand interactions and therapeutically critical immune effector functions, aglycosylated full-length IgG antibodies are nearly identical to the glycosylated counterparts in terms of antigen binding, stability at physiological or low temperature conditions, pharmacokinetics, and biodistribution. To bypass the drawbacks of glycosylated antibodies that include glycan heterogeneity and requirement of high capital investment for biomanufacturing, aglycosylated antibodies have been developed and several are under clinical trials. Comprehensive cellular and bioprocess engineering has enabled to produce highly complex aglycosylated IgGs in a simple bacterial cultivation with comparable production level as that of mammalian cells. Moreover, extensive engineering of aglycosylated Fc has converted the aglycosylated IgG antibodies into a new class of effector functional human immunotherapeutics.
UR - http://www.scopus.com/inward/record.url?scp=84904344421&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84904344421&partnerID=8YFLogxK
U2 - 10.1016/j.copbio.2014.06.013
DO - 10.1016/j.copbio.2014.06.013
M3 - Review article
VL - 30
SP - 128
EP - 139
JO - Current Opinion in Biotechnology
JF - Current Opinion in Biotechnology
SN - 0958-1669
ER -